Publication: Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration
Issued Date
2018-01-01
Resource Type
ISSN
13411357
Other identifier(s)
2-s2.0-85055142822
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental Animals. Vol.67, No.4 (2018), 441-449
Suggested Citation
Prapawadee Pirintr, Vudhiporn Limprasutr, Nakkawee Saengklub, Parnpradub Pavinadol, Napat Yapao, Natthakarn Limvanicharat, Hathaisiri Kuecharoen, Anusak Kijtawornrat Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration. Experimental Animals. Vol.67, No.4 (2018), 441-449. doi:10.1538/expanim.18-0030 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/44864
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration
Other Contributor(s)
Abstract
© 2018 Japanese Association for Laboratory Animal Science. Degenerative mitral valve disease (DMVD) is a common cardiac disease in geriatric dogs characterized by the degeneration of the mitral valve, leading to decreased cardiac output and activation of the sympathetic and renin-angiotensin-aldosterone system. This disease results in an increased resting heart rate (HR) and myocardial oxygen consumption (MVO2). A recent publication demonstrated that dogs with asymptomatic DMVD had a significantly higher HR and systemic blood pressure (BP) than age-matched control dogs. This higher HR will eventually contribute to increased MVO2. This study aimed to determine the effects of a single oral dose of ivabradine on the HR, MVO2 as assessed by the rate-pressure product, and BP in dogs with asymptomatic DMVD. Seven beagles with naturally occurring DMVD were instrumented by the Holter recorder and an oscillometric device to measure electrocardiogram and BP for 24 and 12 h, respectively. Each dog was randomly subjected to receive either placebo or ivabradine (0.5, 1.0 and 2.0 mg/kg). The results revealed that oral administration of ivabradine significantly decreased the HR and rate-pressure product in a dose-dependent manner without adverse effects. The highest dose of 2.0 mg/kg significantly reduced systolic and mean BP. Therefore, the findings imply that a single oral ivabradine administration at a dose of 1.0 mg/kg is suitable for dogs with asymptomatic DMVD to reduce the HR and MVO2 without marked effects on BP. This may potentially make ivabradine promising for management of an elevated HR in DMVD dogs.